Epilepsy is one of the oldest recognized neurological conditions in human medicine, documented in ancient texts from Babylonian, Egyptian, Greek, and Roman civilizations, yet its genetic underpinnings have only begun to be systematically characterized over the past three decades as advances in molecular genetics, genomic sequencing technology, and large-scale collaborative research have illuminated the extraordinary genetic complexity underlying this extraordinarily diverse group of conditions. The recognition that genetic factors contribute to epilepsy risk spans a continuum from the rare monogenic epilepsy syndromes caused by single-gene mutations of large individual effect to the common polygenic epilepsies in which hundreds or thousands of common genetic variants each contribute modest incremental increases to a population-distributed liability that interacts with environmental factors to determine whether clinical seizures develop. This genetic spectrum mirrors the clinical spectrum of epilepsy, which encompasses conditions as distinct as the infantile spasms of West syndrome, the absence seizures of childhood absence epilepsy, the juvenile myoclonic jerks and tonic-clonic seizures of juvenile myoclonic epilepsy, the focal seizures of familial temporal lobe epilepsy, and the devastating drug-resistant seizures of Dravet syndrome.
The clinical importance of understanding the genetic basis of epilepsy has been transformed by the advent of precision medicine approaches that use genetic diagnosis to guide not only seizure management but also the avoidance of treatments that may paradoxically worsen seizures in specific genetic epilepsy syndromes. The recognition that sodium channel blocking anticonvulsants including carbamazepine and lamotrigine can dramatically worsen seizures and overall neurological function in patients with Dravet syndrome caused by SCN1A loss-of-function mutations, because these agents reduce the function of the very sodium channel subunit whose haploinsufficiency causes Dravet syndrome, is perhaps the most clinically consequential example of how genetic diagnosis can prevent iatrogenic harm in epilepsy management. As whole-exome and whole-genome sequencing become increasingly accessible and affordable in clinical practice, the genetic characterization of epilepsy patients is becoming a routine component of diagnostic workup rather than a specialized investigation reserved for academic centers, with important implications for treatment selection, prognostication, genetic counseling, and family screening.
The International League Against Epilepsy recognizes a genetic etiology of epilepsy as one in which the epilepsy is a direct result of a known or presumed genetic defect in which seizures are a core symptom of the disorder, distinguishing this from other etiological categories including structural, metabolic, infectious, immune, and unknown. This classification framework acknowledges that genetic factors can produce epilepsy through diverse mechanisms including the disruption of ion channel function, the impairment of synaptic transmission and plasticity, the dysregulation of cortical development and neuronal migration, the disturbance of metabolic pathways essential for neuronal energy production and neurotransmitter synthesis, and the dysregulation of immune and inflammatory pathways that affect neuronal excitability. Understanding these diverse genetic mechanisms provides both the foundation for mechanism-based treatment approaches and the framework for understanding why genetically distinct epilepsy syndromes differ so profoundly in their clinical presentation, natural history, and treatment response.
Ion Channel Gene Mutations and Channelopathies
The most extensively characterized category of genetic epilepsy is the channelopathies, in which mutations in genes encoding voltage-gated ion channels or ligand-gated neurotransmitter receptors alter the intrinsic excitability properties of neurons in ways that predispose to synchronized, excessive neuronal discharge and clinical seizures. The voltage-gated sodium channels are the most important ion channel family in epilepsy genetics, with mutations in multiple sodium channel subunit genes including SCN1A, SCN2A, SCN3A, SCN8A, and SCN9A identified as causes of distinct epilepsy syndromes that span the severity spectrum from relatively benign self-limited epilepsies to devastating drug-resistant encephalopathies.
SCN1A, encoding the Nav1.1 sodium channel alpha subunit that is particularly important for maintaining the excitability of inhibitory GABAergic interneurons in the cortex and hippocampus, is the most frequently mutated gene in epilepsy and the cause of multiple distinct epilepsy syndromes depending on the nature of the mutation and its functional consequences. Loss-of-function mutations in SCN1A, which reduce Nav1.1 sodium channel activity in the interneurons that depend on it most heavily for maintaining their high-frequency firing capacity, produce Dravet syndrome when present as de novo heterozygous mutations, causing the interneuron dysfunction that reduces inhibitory tone in cortical circuits and thereby promotes the excessive excitatory activity that generates the characteristic febrile and afebrile generalized and focal seizures of this devastating epileptic encephalopathy. Gain-of-function mutations in SCN1A, which increase sodium channel activity and can increase neuronal excitability, cause familial hemiplegic migraine and in some cases epilepsy with a different clinical profile from Dravet syndrome, illustrating how opposite functional consequences of mutations in the same gene can produce distinct clinical phenotypes.
SCN2A, encoding the Nav1.2 sodium channel alpha subunit expressed predominantly in glutamatergic excitatory pyramidal neurons, causes a spectrum of epilepsy syndromes whose clinical severity correlates with the functional consequence of the mutation and the age of seizure onset. Gain-of-function mutations in SCN2A, which increase channel activity and neuronal excitability, produce early infantile epileptic encephalopathy with seizure onset in the first three months of life and a severe clinical course, while loss-of-function mutations produce later-onset epilepsy with a more favorable prognosis or neurodevelopmental disorders without epilepsy, reflecting the different developmental roles of Nav1.2 in immature versus mature neurons. SCN8A gain-of-function mutations cause a severe infantile onset epileptic encephalopathy with prominent intellectual disability and movement disorder that, unlike Dravet syndrome, shows beneficial responses to sodium channel blocking medications because the mutations increase rather than decrease excitatory sodium channel function.
Voltage-gated potassium channels are the second major ion channel family implicated in genetic epilepsy, with mutations in KCNQ2, KCNQ3, KCNT1, KCNA2, and KCNB1 among the genes most commonly associated with epilepsy phenotypes. KCNQ2 and KCNQ3, encoding the Kv7.2 and Kv7.3 potassium channel subunits that form the M-current which regulates neuronal firing frequency and the transition from quiescent to active states, cause benign neonatal familial seizures when mutant channels produce modest loss of function but cause severe neonatal epileptic encephalopathy when mutations produce more profound channel dysfunction. The clinical recognition of KCNQ2-related neonatal encephalopathy has important therapeutic implications because the sodium channel blocker phenytoin is often effective for seizure control in this condition, while the standard neonatal anticonvulsant phenobarbital may be less effective, and targeted treatment with the potassium channel opener ezogabine has shown promise in some reported cases.
Developmental and Synaptic Gene Mutations
Beyond ion channelopathies, a large and growing group of epilepsy-associated genetic mutations affects genes involved in neuronal development, synaptic function, and the molecular machinery that regulates cortical circuit formation and plasticity. Mutations in these genes produce epilepsy through the dysregulation of the excitatory-inhibitory balance of cortical circuits that is established during fetal and early postnatal brain development and that, when disrupted, creates a neuronal network substrate that is chronically predisposed to synchronous pathological discharge.
GRIN2A mutations, identified through large-scale sequencing studies of families with epilepsy-aphasia spectrum disorders, affect the GluN2A subunit of the NMDA glutamate receptor and are associated with a spectrum of epilepsy syndromes including childhood epilepsy with centrotemporal spikes, Landau-Kleffner syndrome, and continuous spike-waves during slow-wave sleep, conditions united by the presence of epileptic activity specifically during non-REM sleep that produces the language and cognitive regression characteristic of these syndromes. GRIN2B mutations, affecting the GluN2B subunit expressed predominantly in early postnatal life, cause severe epileptic encephalopathy with prominent intellectual disability and autistic features that reflects the critical role of GluN2B-containing NMDA receptors in synaptogenesis and activity-dependent synaptic refinement during early brain development.
CDKL5 mutations cause a severe X-linked epileptic encephalopathy, CDKL5 deficiency disorder, characterized by early onset intractable seizures, absence of speech, and profound intellectual disability, reflecting the critical role of this serine-threonine kinase in activity-dependent synaptic signaling and dendritic spine morphology regulation. STXBP1 mutations affecting the syntaxin-binding protein 1 that is essential for vesicle docking and neurotransmitter release at synaptic terminals cause Ohtahara syndrome when detected in the neonatal period and a broader spectrum of epileptic encephalopathy when identified in older patients, with the seizure profile evolving from the characteristic suppression-burst electroencephalogram of Ohtahara syndrome through infantile spasms to the multifocal and generalized seizures of later childhood. The mTOR pathway genes TSC1 and TSC2, mutations in which cause tuberous sclerosis complex with its characteristic tubers, cortical dysplasia, and drug-resistant seizures, represent another important class of developmental epilepsy genes whose hyperactivation of mechanistic target of rapamycin signaling disrupts neuronal migration, cortical lamination, and synaptic connectivity in ways that create profoundly epileptogenic cortical microstructures.
Polygenic and Common Epilepsies
The most prevalent epilepsy syndromes including juvenile myoclonic epilepsy, childhood absence epilepsy, generalized epilepsy with febrile seizures plus, and focal epilepsy with variable genetic contribution are characterized by polygenic inheritance in which multiple common genetic variants, individually of small effect, collectively influence epilepsy liability through their combined impact on neuronal excitability, ion channel expression, synaptic transmission efficiency, and the threshold for seizure generation. Genome-wide association studies of epilepsy have identified dozens of common genetic loci associated with different epilepsy syndromes, with the implicated genes enriched for those encoding ion channels, synaptic proteins, and neurodevelopmental regulators, providing genetic validation of the mechanistic hypotheses derived from single-gene epilepsy research.
Juvenile myoclonic epilepsy, one of the most common genetic generalized epilepsy syndromes, is characterized by myoclonic jerks on awakening, generalized tonic-clonic seizures, and in many patients absence seizures, typically beginning in adolescence and persisting lifelong in the majority of patients, though seizure control is achieved with appropriate medications in approximately eighty percent of patients who adhere to treatment. The syndrome is associated with multiple genetic susceptibility loci identified through genome-wide association studies and candidate gene approaches, with no single gene accounting for more than a small proportion of cases and with the overall genetic architecture consistent with a highly polygenic disorder whose liability is continuously distributed in the population rather than segregating in families as a simple Mendelian trait. The lifetime requirement for anti-seizure medication in most juvenile myoclonic epilepsy patients, the sensitivity of seizures to sleep deprivation and alcohol, and the specific medication sensitivities including the potentially paradoxical worsening with carbamazepine in some patients are important clinical features whose understanding benefits from appreciation of the polygenic genetic architecture.
Genetic counseling in epilepsy requires careful consideration of the specific genetic architecture of the epilepsy syndrome in the individual patient and family, the penetrance and expressivity of the identified genetic abnormality, the reproductive implications for affected individuals and their relatives, and the psychological impact of genetic information on the patient’s self-understanding and family relationships. For de novo mutations causing severe epileptic encephalopathies, where the affected individual is unlikely to reproduce and recurrence risk for future offspring of the parents is low but non-zero due to gonadal mosaicism, the counseling focus is on the natural history of the condition and supportive care planning rather than reproductive decision-making. For autosomal dominant epilepsy syndromes with variable expressivity, where first-degree relatives have a fifty percent risk of carrying the mutation but variable probability of developing clinical epilepsy depending on penetrance, the counseling must address both the risk of seizure disorder and the range of clinical outcomes that mutation carriers may experience.